EGFR and breast carcinoma: Recently, we reported that IRS-1 can interact with EGFR, resulting in loss of recruitment of IRS-1 by IGF-IR and reducing signalling via this receptor in an ER+, tamoxifen-resistant MCF-7 breast cancer cell line [29].